GnRH-a has been widely used preceding the stimulation with gonadotropins for in vitro fertilization- 
presented with functional ovarian cysts during administration of luteal phase GnRH-a. We defined a funcThe use of gonadotropin-releasing hormone (GnRH) tional cyst as a round, well-limited, anechoic structure, analogue (GnRH-a) to induce ovarian suppression was with a diameter Ͼ15 mm in the ultrasound at the time of the postsuppression control, accompanied by serum of ovarian function and a resting endometrium with an E 2 level Յ 50 pg/ml. Controlled ovarian hyperstimulation was performed with 300 IU of recombinant, started in this group, we confirmed ovarian suppression high purified, or pure follicle-stimulating hormone with a serum estradiol level Ͻ 50 pg/ml. (FSH) (Gonal-F, Metrodine HP, Serono, Argentina;
Statistical evaluation was performed using student's Follitrin, Massone, Argentina), or with a combination t and 2 tests. Statistical significance was defined as of 150 IU of FSH and 150 IU of human menopausal P Ͻ 0.05, and the results are expressed as mean Ϯ SD. gonadotropin (hMG) (Pergonal 1000, Serono, Argentina; hMG Massone, Argentina) according to physician's criteria, and at that time, the analogue was RESULTS decreased to 0.5 or 0.25 mg/day. Ovarian monitoring was started on day 5 of the stimulation with vaginal An incidence of functional ovarian cysts of 5.5% ultrasounds and serum E 2 determinations, and was (59 cases out of 936 procedures performed during repeated every 24-48 hr as required in each case. A the studied period) in GnRH-a treated patients was dose of 10,000 IU of human chorionic gonadotropin detected. Both groups were similar in terms of cause (hCG) (Profasi HP, Serono, Argentina) was adminisof infertility and dose of the analogue. There were no tered when at least two follicles Ͼ16 mm were visualsignificant differences between groups A and B in ized. Oocyte aspiration was performed 35 hr after hCG terms of age, basal FSH and luteinizing hormone (LH) administration under vaginal ultrasound guidance. Ferlevels, and FSH:LH ratio (Table I) . Serum E 2 levels tilization was achieved through IVF or ICSI. Embryo post-GnRH-a suppression, E 2 on the day of hCG, numtransfer was performed using a Frydman cannula 48 ber of oocytes retrieved, fertilization rate, number of hr after oocyte retrieval. A daily dose of 800 mg embryos transferred, implantation rate, and clinical micronized progesterone was administered transvagipregnancy rate per transfer (defined as transvaginal nally (Utrogestan, Rontag, France), beginning on the ultrasound visualization of a gestational sac at 6 weeks day after oocyte retrieval and until the confirmation gestational age) were also similar, as shown in Table II . of pregnancy; progesterone was continued thereafter
In group A, 15 clinical pregnancies were obtained, until the 12th week of gestation.
3 of which were twin pregnancies and 4 ended in Ultrasonography was performed using an endovagiclinical miscarriages (1 twin). In group B, 5 clinical nal 7.5 mHz transducer and an Aloka SSD-680 unit pregnancies were diagnosed, 3 of which were twin (Aloka Co. Ltd., Japan). Serum E 2 was determined pregnancies and 2 ended in clinical miscarriages (1 by the COAT-A COUNT IRMA Kit (Diagnostic Products twin). Finally, the implantation and clinical pregnancy Corporation, Los Angeles, CA), a solid-phase immurates also were not statistically different, although a noradiometric assay. Intrerassay and intra-assay coeffitrend in favor of group B was observed. cient of variation were 5.9% and 4.9%, respectively.
All patients who developed cysts between the beginning of the treatment with GnRH-a and the start of DISCUSSION controlled ovarian hyperstimulation (COH) were divided in two groups. Group A consisted of 45
One of the most frequent complications of the patients (41 embryo transfers), in which conservative administration of GnRH-a is the formation of funcmanagement was used. COH was begun when serum tional ovarian cysts, regardless of the protocol used estradiol level was Ͻ 50 pg/ml. Group B included 14 (luteal or follicular long protocol or short flare-up propatients (13 embryo transfers), in which the cyst was tocol). The incidence of the formation of these cysts is quite variable. Jenkins et al. (7) reported an incidence aspirated under ultrasound guidance. Before COH was (3) found approximately 25%. These discrepancies between different reports could be due to different Keltz et al. (9) reported that the formation of these cysts is an indication of poor response, as well as a definitions of cyst, between 10 and 30 mm, as well as to different times of administration and dose of the reliable predictor of poor stimulation and low pregnancy rates in IVF-ET cycles, but they did not establish analogue. An average incidence of 13.6% was reported by Herman et al. (4) in 1990. In our study, we detected a norm to handle these particular type of patients. RonEl et al. (6) demonstrated that conservative manage-59 cases from the 936 procedures performed during the period studied, which represents an incidence of 5.5%. ment of these patients does not significantly affect either the number or the quality of the oocytes and Jenkins et al. (5) demonstrated in 1993 that these cysts are of follicular origin. It was suggested that embryos. However, in this study, the cysts were formed during the administration of the analogue, beginning the cysts are formed from immature antral follicles in response to the initial flare up generated by the GnRHin the follicular phase. But, as demonstrated in our study, even if the analogue administration is begun in a. The subsequent desensitization of the hypophysis inhibits the LH surge, generating a disorder in follicular the luteal phase, the quantity and quality of the embryos obtained (Table II) does not vary significantly growth and formation of the cyst. The E 2 levels therefore can continue to be elevated from an active cyst in comparison with the patients who did not present functional ovarian cysts. Tarlatzis et al. (12) did not production, despite the pituitary suppression achieved with the GnRHa. find significant differences regarding the number of follicles and oocytes in those patients who developed There are different mechanisms through which these cysts can influence ART results. The first is a funccysts that were punctured and in those who did not develop cysts. He suggests the convenience of puncturtional endocrine effect with disruption of early stages of the follicles. Another mechanism is by premature ing the cysts more from a clinical impression than scientific criteria. luteinization and elevation on the serum progesterone (lutein cyst). The third is mechanical through a reducNo other study in the literature reviewed compares the different ways of managing this specific type of tion of space for follicle growth, or through impairment of the ovarian blood flow.
functional cyst produced after the administration of GnRHa in the luteal phase. Therefore, our study Rizk et at. (8) demonstrated that there are no significant differences in IVF results whether the cysts are intended to contribute new data to establish guidelines in the management of this specific situation. aspirated or conservative management is used. However, they do not discriminate whether these cysts are functional or not, or the time during the cycle that the suppressor therapy was administered. We agree with CONCLUSIONS their conclusion, because no significant differences were found in our material between both groups in According to our results, the aspiration of functional ovarian cysts under transvaginal ultrasound guidance, terms of final results. It has been demonstrated that the failure to achieve an E 2 suppression level in the compared to an expected behavior, after obtaining ovarian suppression (E 2 Յ 50 pg/ml), and before beginpresence of functional ovarian cysts does not necessar- 
